White blood cells >= /uL, within weeks of randomization White blood cells (WBC) >= , cells/uL (. x ^ L) or Obtained within days prior to course day (CD): White blood cells (WBC) >= /uL White blood cells (WBC) >= /uL White blood cells (WBC) >= ,/uL Within days of the first dose of study drug: White blood cells (WBCs) >= /uL White blood cell (WBC) >= , cells/uL Leukocytes (white blood cells [WBCs]) >= ,/uL. White blood cells (WBCs) >= /microL within days of study registration. STUDY TREATMENT: White blood cells (WBC) >= /ul White blood cells (WBC) >= ,/uL White blood cells (WBC) >= /uL within days prior to first dose White blood cells (WBC) >= /uL White blood cells >= /uL obtained < weeks prior to starting treatment Obtained within days of randomization: White blood cells (WBCs) >= /uL White blood cells (WBC)\t>= ,/uL White blood cell (WBC) >= cells/uL (obtained within days prior to first study treatment) White blood cells (WBC) >= /uL White blood cells (WBC) >= /uL White blood cells (WBC) =< ,/uL White blood cells (WBC) >= ,/uL White blood cells (WBC) >= /uL White blood cells (WBC) is >= /ul White blood cells (WBC) >= /uL White blood cells (WBC) >= ,/uL Patients must have lymphocytosis with white blood cells between ,-,/uL in order to collect adequate leukemia cells for vaccine production White blood cell (WBC) >= , cells/uL White blood cells (WBC) >= ,/ul White blood cells (WBC) >= ,/ul White blood cells (WBC) >= x ^/ul White blood cells (WBC) >= /ul performed within days of enrollment Total absolute phagocyte count (APC = [%neutrophils + %monocytes) x white blood cells [WBC]) is at least /uL White blood cells (WBC) >= /uL White blood cells /ul or more White blood cells (WBC) >= /uL White blood cells (WBC) >= /uL White blood cell (WBC) >= , cells/uL White blood cells (WBC) >= /uL White blood cell (WBC) >= , cells/uL White blood cells (WBCs) >= cells/uL White blood cells (WBCs) >= cells u/L White blood cells (WBCs) >= /uL White blood cells (WBCs) >= /uL Prior to cyclophosphamide and T cell infusions: white blood cells (WBC) =< /uL Within days prior to registration: white blood cells (WBC) >= ,/uL White blood cells (WBC) > /uL Within days prior to the first study treatment (cycle , day ): White blood cells (WBC) counts > /uL White blood cells (WBCs) >= /uL White blood cells (WBC) > /ul White blood cells (WBC) < ,/ul White blood cells (WBC) >= cells/ul White blood cell (WBC) >= , cells/uL White blood cells (WBC) >= /uL White blood cells (WBC) >= /uL White blood cells (WBC) >= /ul White blood cells (WBC) =< /uL COHORT A: White blood cells (WBC) >= /uL White blood cells (WBC) >= /uL White blood cells (WBC)\t>= /uL Obtained within days prior to registration: White blood cells (WBC) >= ,/ul White blood cells (WBC) >= /uL White blood cells (WBC): >= /uL (~ x ^/L) White blood cells (WBC) >= ,/ul White blood cells (WBC) > . K/uL Within days prior to enrollment/randomization: White blood cells (WBC) >= . K/uL White blood cells (WBC) >= . x ^/uL White blood cells (WBC) >= . x ^/uL White blood cells (WBC) < ,/ul at screening White blood cells greater than . x ^/ul (or , cells/mm^); these results can be within last days from the day of signing informed consent White blood cells (WBC) >= ,/ul White blood cells (WBC) >= /uL White blood cells (WBC) >= ,/uL Severe leukocytosis (white blood cell count [WBC] >= , cells /uL) White blood cells (WBCs) >= /uL, obtained within days of the first dose of study drug White blood cells (WBCs) < . K/UL in the past days White blood cells (WBCs) < . K/UL in the past days Leukocytes (white blood cells [WBC]) >= ,/uL (>= ,/uL for African-American participants) White blood cells (WBC) > cells/uL Within days of eligibility confirmation: Leukocytes (white blood cells [WBC]) >= ,/uL Obtained within days prior to registration: White blood cell (WBC) >= cells/uL White blood cells >= ,/uL White blood cells (WBC) > . X ^/uL